Literature DB >> 23942788

Transient autoimmune hyperthyroidism following the withdrawal of Natalizumab in patients with multiple sclerosis.

María Carcelén-Gadea1, Juan Carlos Ferrer-Garcia, Angeles Cervelló Donderis.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23942788     DOI： 10.1007/s10072-013-1497-3

Source DB:  PubMed          Journal:  Neurol Sci        ISSN： 1590-1874            Impact factor:   3.307


× No keyword cloud information.
  9 in total

1.  Immune reconstitution inflammatory syndrome in natalizumab-associated PML.

Authors:  I L Tan; J C McArthur; D B Clifford; E O Major; A Nath
Journal:  Neurology       Date:  2011-08-10       Impact factor: 9.910

Review 2.  The effect of medications on thyroid function tests.

Authors:  Priya Kundra; Kenneth D Burman
Journal:  Med Clin North Am       Date:  2012-03       Impact factor: 5.456

3.  Hashimoto's thyroiditis presenting as acute painful thyroiditis and as a manifestation of an immune reconstitution inflammatory syndrome in a human immunodeficiency virus-seropositive patient.

Authors:  Roos Visser; Quirijn de Mast; Romana T Netea-Maier; Andre J A M van der Ven
Journal:  Thyroid       Date:  2012-07-11       Impact factor: 6.568

4.  Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis.

Authors:  P W O'Connor; A Goodman; L Kappos; F D Lublin; D H Miller; C Polman; R A Rudick; W Aschenbach; N Lucas
Journal:  Neurology       Date:  2011-05-04       Impact factor: 9.910

Review 5.  Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring.

Authors:  Ludwig Kappos; David Bates; Gilles Edan; Mefkûre Eraksoy; Antonio Garcia-Merino; Nikolaos Grigoriadis; Hans-Peter Hartung; Eva Havrdová; Jan Hillert; Reinhard Hohlfeld; Marcelo Kremenchutzky; Olivier Lyon-Caen; Ariel Miller; Carlo Pozzilli; Mads Ravnborg; Takahiko Saida; Christian Sindic; Karl Vass; David B Clifford; Stephen Hauser; Eugene O Major; Paul W O'Connor; Howard L Weiner; Michel Clanet; Ralf Gold; Hans H Hirsch; Ernst-Wilhelm Radü; Per Soelberg Sørensen; John King
Journal:  Lancet Neurol       Date:  2011-08       Impact factor: 44.182

6.  [HIV-therapy-associated immune reconstitution syndrome presenting as immunogenic hyperthyroidism].

Authors:  N A H Ho; R E Schmidt; G Behrens
Journal:  Dtsch Med Wochenschr       Date:  2010-05-31       Impact factor: 0.628

7.  The expression of adhesion molecules in thyroid glands from patients with Graves' disease.

Authors:  M Nakashima; K Eguchi; H Ida; I Yamashita; M Sakai; T Origuchi; Y Kawabe; N Ishikawa; K Ito; S Nagataki
Journal:  Thyroid       Date:  1994       Impact factor: 6.568

8.  Adhesion molecules from the LFA-1/ICAM-1,3 and VLA-4/VCAM-1 pathways on T lymphocytes and vascular endothelium in Graves' and Hashimoto's thyroid glands.

Authors:  M Marazuela; A A Postigo; A Acevedo; F Díaz-González; F Sanchez-Madrid; M O de Landázuri
Journal:  Eur J Immunol       Date:  1994-10       Impact factor: 5.532

9.  Interferon beta-1b treatment does not induce autoantibodies.

Authors:  C H Polman; L Kappos; F Dahlke; R Graf; K Beckmann; T Bogumil; C Pozzilli; A J Thompson
Journal:  Neurology       Date:  2005-03-22       Impact factor: 9.910
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.